Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BEGRIVAC · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BEGRIVAC | BIOLOGICAL | 126 healthy subjects enrolled to receive, in open-label manner, one dose of Begrivax (influenza vaccine) |
Inclusion Criteria: 1. Male and female volunteers of 18 years of age and older, mentally competent, willing and able to give written informed consent prior to study entry; 2. Individuals able to comply with all the study requirements; 3. Individuals in good health as determined by medical history, ...
BEGRIVAC is a seasonal influenza vaccine used for the prevention of seasonal influenza. It is a monovalent or multivalent inactivated split influenza vaccine designed to provide immunity against circulating influenza strains. The vaccine is intended for use in adults aged 18 years and older.
BEGRIVAC is developed by Novartis AG, a multinational pharmaceutical company listed on the New York Stock Exchange under the ticker symbol NVS. The vaccine is part of Novartis's infectious disease portfolio, focusing on seasonal influenza prevention.
BEGRIVAC is in Phase 3 clinical development. It has completed one Phase 3 trial, which evaluated its safety and immunogenicity. The vaccine is investigational and not yet approved for widespread use, as it remains under clinical evaluation.
BEGRIVAC has been studied in one completed Phase 3 clinical trial with the identifier NCT01147081. This trial assessed the safety and immunogenicity of the inactivated split influenza vaccine using the 2010/2011 strain composition. The study enrolled 142 healthy adult volunteers in Germany.
BEGRIVAC works by stimulating the immune system to produce antibodies against influenza viruses. As an inactivated split vaccine, it contains disrupted viral particles that cannot cause disease but are recognized by the body, triggering a protective immune response against seasonal influenza strains.